Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis
Bicistronic-CD19/22 CAR-T therapy has induced sustained remission in pediatric patients with refractory LN. Although the treatment triggered severe complications-HLH/TMA. These complications were manageable with aggressive supportive therapy, underscoring the importance of meticulous patient screening before CAR-T administration. This therapy offers a promising treatment strategy for refractory LN.
Authors
- Chenxing Zhang
- Juan Qian
- Benshang Li
- Jiayao Shen
- Yanjing Tang
- Youying Mao
- Kang An (ORCID: https://orcid.org/0000-0003-4937-4567)
- Weidong Shen (ORCID: https://orcid.org/0000-0003-0021-3885)
- Lei Yin (ORCID: https://orcid.org/0000-0003-4795-8710)
Institutions
- Shanghai Children's Medical Center (CN)
- Tongren Hospital (CN)
- Songjiang District Central Hospital (CN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1016/j.ekir.2025.10.008
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00